{"id":"6457210cbaae","type":"article","url":"https://hartvaat.nl/2021/12/07/gold-force-multi-elektrode-rf-versus-irrigated-rf-bij-af-gerandomiseerde-trial/","title":"GOLD FORCE multi-elektrode RF versus irrigated RF bij AF: gerandomiseerde trial","title_en":"Efficacy and safety of the GOLD FORCE multicentre randomized clinical trial: multielectrode phased radiofrequency vs. irrigated radiofrequency single-tip catheter with contact force ablation for treatment of symptomatic paroxysmal atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab168","source_url":"https://doi.org/10.1093/europace/euab168","authors":["Lisette I S Wintgens","Martijn N Klaver","Moniek Maarse","Stefan G Spitzer","Anke Langbein","Martin J Swaans","Vincent F Van Dijk","Jippe C Balt","Maurits C E F Wijffels","Jan G P Tijssen","Arif Elvan","Lucas V A Boersma"],"significance":5,"published":"2021-12-07","source_date":"2021-12-07","image":"","kennis":[],"congress":"","summary_en":"The GOLD FORCE trial compared multielectrode phased RF ablation with irrigated RF ablation for AF, evaluating a balloon-based multielectrode technology against the conventional single-tip approach.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T13:28:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"GOLD FORCE gerandomiseerde trial die multi-elektrode phased RF vergeleek met geïrrigeerde RF-ablatie bij AF.","abstract_original":"AIMS: Pulmonary vein isolation (PVI) for atrial fibrillation (AF) has become increasingly safe and effective with the evolution of single-tip ablation catheters aided by contact force sensing (ST-CF) and single-shot devices such as the second-generation pulmonary vein ablation catheter (PVAC) Gold multi-electrode array. The multicentre randomized GOLD FORCE trial was conducted to evaluate non-inferiority of safety and efficacy of PVAC Gold PVI compared to ST-CF ablation for paroxysmal AF. METHODS AND RESULTS: The primary efficacy endpoint documented AF recurrence ≥30 s was assessed by time-to-first-event analysis after a 90-day blanking period using repeated 7-day Holters. Secondary endpoints include acute success and procedural characteristics. Safety endpoints included procedural complications, stroke/transient ischaemic attack (TIA), tamponade, bleeding, and access site complications. Two hundred and eight patients underwent randomization and PVI (103 assigned to PVAC Gold, 105 to ST-CF). Acute success rates were 95% and 97% for PVAC Gold and ST-CF, respectively. At 12 months, AF recurrence was observed in 46.6% of the PVAC Gold group and in 26.2% of the ST-CF group [absolute efficacy difference 20.4% (95% confidence interval, CI 7.5-33.2%), hazard ratio 2.05 (95% CI 1.28-3.29), P = 0.003]. PVAC Gold had significantly shorter procedure and ablation times. Complication rates were 5.7% and 4.9% for PVAC Gold and ST-CF, respectively (P = 0.782). CONCLUSION: In this multicentre randomized clinical trial, ablation with ST-CF and PVAC Gold ablation catheters non-inferiority for efficacy was not met. AF recurrence was significantly more frequent in the PVAC Gold group compared to single-tip contact force group. Both groups had similarly low rates of adverse events. PVAC Gold ablation had significantly shorter procedure and ablation times."}